These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19381770)

  • 1. Continuous dopaminergic stimulation achieved by duodenal levodopa infusion.
    Odin P; Wolters E; Antonini A
    Neurol Sci; 2008 Dec; 29 Suppl 5():S387-8. PubMed ID: 19381770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study.
    Zibetti M; Merola A; Ricchi V; Marchisio A; Artusi CA; Rizzi L; Montanaro E; Reggio D; De Angelis C; Rizzone M; Lopiano L
    J Neurol; 2013 Jan; 260(1):105-14. PubMed ID: 22772358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbidopa levodopa enteral suspension.
    Seeberger LC; Hauser RA
    Expert Opin Pharmacother; 2015; 16(18):2807-17. PubMed ID: 26595228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
    Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
    Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Levodopa intestinal infusion therapy in Parkinson's disease].
    Sławek J; Bogucki A
    Neurol Neurochir Pol; 2010; 44(4):396-403. PubMed ID: 20827613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duodenal levodopa infusion for the treatment of Parkinson's disease.
    Samanta J; Hauser RA
    Expert Opin Pharmacother; 2007 Apr; 8(5):657-64. PubMed ID: 17376020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
    Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term experience with continuous duodenal levodopa-carbidopa infusion (Duodopa): report of six patients.
    Raudino F; Garavaglia P; Pianezzola C; Riboldazzi G; Leva S; Guidotti M; Bono G
    Neurol Sci; 2009 Feb; 30(1):85-6. PubMed ID: 19169622
    [No Abstract]   [Full Text] [Related]  

  • 13. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure.
    Nyholm D; Lewander T; Johansson A; Lewitt PA; Lundqvist C; Aquilonius SM
    Clin Neuropharmacol; 2008; 31(2):63-73. PubMed ID: 18382177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection.
    Abbruzzese G; Barone P; Bonuccelli U; Lopiano L; Antonini A
    Funct Neurol; 2012; 27(3):147-54. PubMed ID: 23402675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experience with continuous levodopa enteral infusion (Duodopa(®)) in patients with advanced Parkinson's disease in a secondary level hospital].
    Santos-García D; Macías M; Llaneza M; Fuster-Sanjurjo L; Echarri-Piudo A; Belmonte S; Blanco S
    Neurologia; 2010; 25(9):536-43. PubMed ID: 21093702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myths and realities of continuous dopaminergic stimulation.
    Pirtošek Z
    Psychiatr Danub; 2011 Mar; 23(1):80-3. PubMed ID: 21448103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
    Nyholm D
    Clin Pharmacokinet; 2006; 45(2):109-36. PubMed ID: 16485914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets.
    Nyholm D; Askmark H; Gomes-Trolin C; Knutson T; Lennernäs H; Nyström C; Aquilonius SM
    Clin Neuropharmacol; 2003; 26(3):156-63. PubMed ID: 12782919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review.
    Cabreira V; Soares-da-Silva P; Massano J
    Drugs; 2019 Apr; 79(6):593-608. PubMed ID: 30905034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.